We narrowed to 161 results for: cel=

#137138-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-Coff/Fon-oScarlet (#137138). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Coff/Fon-oScarlet plasmid DNA. EF1a-driven, Flp-dependent expression of oScarlet (inhibited in presence of Cre). These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

April 8, 2021

Academic Institutions and Nonprofits only

#137157-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-Coff/Fon-iC++-EYFP (#137157). In addition to the viral particles, you will also receive purified pAAV-nEF-Coff/Fon-iC++-EYFP plasmid DNA. nEF-driven, Flp-dependent expression of chloride-conducting channelrhodopsin iC++-EYFP (inhibited in presence of Cre) for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

Feb. 23, 2021

Academic Institutions and Nonprofits only

#75469-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-Flp-DOG-NW (#75469). In addition to the viral particles, you will also receive purified pAAV-EF1a-Flp-DOG-NW plasmid DNA. EF1a-driven expression of Flp recombinase dependent on GFP (Flp-DOG); to be coinjected with GFP (or for use with transgenic GFP animals). These AAV preparations are suitable purity for injection into animals.

Connie Cepko

Tang et al Elife. 2016 May 20;5. pii: e15312. doi:

Feb. 19, 2020

Academic Institutions and Nonprofits only

#137139-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-Con/Fon-ChR2(ET/TC)-EYFP (#137139). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Fon-ChR2(ET/TC)-EYFP plasmid DNA. nEF-driven, Cre and Flp-dependent expression of ChR2(E123T/T159C)-EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

May 19, 2021

Academic Institutions and Nonprofits only

#137140-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-Con/Foff 2.0-ChR2(ET/TC)-EYFP (#137140). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Foff 2.0-ChR2(ET/TC)-EYFP plasmid DNA. nEF-driven, Cre-dependent expression of ChR2(E123T/T159C)-EYFP (inhibited in presence of Flp) for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

May 6, 2021

Academic Institutions and Nonprofits only

#137150-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-Coff/Fon-Arch3.3-p2a-EYFP (#137150). In addition to the viral particles, you will also receive purified pAAV-nEF-Coff/Fon-Arch3.3-p2a-EYFP plasmid DNA. nEF-driven, Flp-dependent expression of Arch3.3-EYFP (inhibited in presence of Cre) for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

May 5, 2021

Academic Institutions and Nonprofits only

#137143-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-Con/Foff 2.0-ChR2-mCherry (#137143). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Foff 2.0-ChR2-mCherry plasmid DNA. nEF-driven, Cre-dependent expression of ChR2-mCherry for optogenetic activation (inhibited in the presence of Flp recombinase). These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

Feb. 25, 2021

Academic Institutions and Nonprofits only

#137129-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-Con/Fon-BFP (#137129). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Con/Fon-BFP plasmid DNA. EF1a-driven, Cre and Flp-dependent expression of BFP. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

April 8, 2021

Academic Institutions and Nonprofits only

#55636-AAV11

Ready-to-use AAV11 particles produced from pAAV-EF1a-Cre (#55636). In addition to the viral particles, you will also receive purified pAAV-EF1a-Cre plasmid DNA. EF1a-driven expression of Cre recombinase. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

July 16, 2025

Academic Institutions and Nonprofits only

#26966-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-Ef1a-DIO eNpHR 3.0-EYFP (#26966). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO eNpHR 3.0-EYFP plasmid DNA. EF1a-driven, cre-dependent eNpHR 3.0-EYFP for optogenetic inhibition. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Gradinaru et al Cell. 2010 Apr 2. 141(1):154-65.

March 27, 2024

Academic Institutions and Nonprofits only

#137153-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-Con/Foff 2.0-NpHR3.3-EYFP (#137153). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Foff 2.0-NpHR3.3-EYFP plasmid DNA. nEF-driven, Cre-dependent expression of NpHR3.3-EYFP (inhibited in presence of Flp) for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

April 8, 2021

Academic Institutions and Nonprofits only

#112677-AAV9

Ready-to-use AAV9 particles produced from pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP (#112677). In addition to the viral particles, you will also receive purified pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP plasmid DNA. EF1a-driven, Cre-dependent color switch. This AAV directs expression of nuclear mCherry in the absence of Cre. In the presence of Cre, nuclear EGFP (and not mCherry) will be expressed. These AAV preparations are suitable purity for injection into animals.

Brandon Harvey

Back et al Neuron. 2019 Feb 8. pii: S0896-6273(19)3

Sept. 8, 2020

Academic Institutions and Nonprofits only

#140135-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV-EF1a-iCreV (#140135). In addition to the viral particles, you will also receive purified pAAV-EF1a-iCreV plasmid DNA. EF1a-driven, light-inducible iCreV recombinase for spatiotemporally precise optogenomic modifications. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Hongkui Zeng

Yao et al Nat Methods. 2020 Mar 23. pii: 10.1038/s

Sept. 15, 2021

Academic Institutions and Nonprofits only

#137149-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-Con/Foff 2.0-Arch3.3-EYFP (#137149). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Foff 2.0-Arch3.3-EYFP plasmid DNA. nEF-driven, Cre-dependent expression of Arch3.3-EYFP (inhibited in presence of Flp) for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

May 6, 2021

Academic Institutions and Nonprofits only

#209655-AAV5

Ready-to-use AAV5 particles produced from pAAV.CAGFLEX.(cyto).iATPSnFR2.S29W.A95K.HaloTag (#209655). In addition to the viral particles, you will also receive purified pAAV.CAGFLEX.(cyto).iATPSnFR2.S29W.A95K.HaloTag plasmid DNA. CAG-driven, Cre-dependent expression of the high affinity ATP biosensor iATPSnFR2. These AAV preparations are suitable purity for injection into animals.

Tim Brown, HHMI-JRC Tool Translation Team

Marvin et al Proc Natl Acad Sci U S A. 2024 May 21;12

Oct. 21, 2024

Academic Institutions and Nonprofits only

#55638-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-EF1a-vCre (#55638). In addition to the viral particles, you will also receive purified pAAV-EF1a-vCre plasmid DNA. EF1a-driven expression of VCre. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

Nov. 12, 2020

Academic Institutions and Nonprofits only

#69571-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-C-CreintG (#69571). In addition to the viral particles, you will also receive purified pAAV-EF1a-C-CreintG plasmid DNA. EF1a-driven expression of optimized C-terminal component of Cre recombinase dependent on GFP (Cre-DOG OPT); to be coinjected with pAAV-EF1a-N-CretrcintG (Addgene catalog# 69570) and GFP (or for use with transgenic GFP animals). These AAV preparations are suitable purity for injection into animals.

Connie Cepko

Tang et al Nat Neurosci. 2015 Sep;18(9):1334-41. do

Feb. 19, 2020

Academic Institutions and Nonprofits only

#69570-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-N-CretrcintG (#69570). In addition to the viral particles, you will also receive purified pAAV-EF1a-N-CretrcintG plasmid DNA. EF1a-driven expression of optimized N-terminal component of Cre recombinase dependent on GFP (Cre-DOG OPT); to be coinjected with pAAV-EF1a-C-CreintG (Addgene catalog# 69571) and GFP (or for use with transgenic GFP animals). These AAV preparations are suitable purity for injection into animals.

Connie Cepko

Tang et al Nat Neurosci. 2015 Sep;18(9):1334-41. do

Feb. 19, 2020

Academic Institutions and Nonprofits only

#112677-AAV2

Ready-to-use AAV2 particles produced from pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP (#112677). In addition to the viral particles, you will also receive purified pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP plasmid DNA. EF1a-driven, Cre-dependent color switch. This AAV directs expression of nuclear mCherry in the absence of Cre. In the presence of Cre, nuclear EGFP (and not mCherry) will be expressed. These AAV preparations are suitable purity for injection into animals.

Brandon Harvey

Back et al Neuron. 2019 Feb 8. pii: S0896-6273(19)3

Jan. 17, 2020

Academic Institutions and Nonprofits only

#137137-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-Con/Foff 2.0-oScarlet (#137137). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Con/Foff 2.0-oScarlet plasmid DNA. EF1a-driven, Cre-dependent expression of oScarlet (inhibited in presence of Flp). These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

April 8, 2021

Academic Institutions and Nonprofits only